I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma
I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma
I-123-MIBG is used to image patients with neuroblastoma, pheochromocytoma and other neural
 crest tumors
Entry criteria--Histologically documented neuroblastoma or pheochromocytoma or strong
 suspicion of neuroblastoma or pheochromocytoma.

 Exclusion criteria--Pregnancy Randomization--None Procedure--Patients will receive a dose of
 I-123-MIBG by intravenous injection. Images will obtained at 18-24 hours after administration
 of the drug and at 42-48 hours as needed. SSKI will be used to block thyroid uptake of free
 I-123-iodide
Inclusion Criteria:

 -  Histologically proven neuroblastoma or pheochromocytoma or strong suspicion of
 neuroblastoma or pheochromocytoma

 Exclusion Criteria:

 -  Pregnancy